Arcutis Biotherapeutics ARQT
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -70.8x
#2874 of 2993 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 80th percentile, 5-year average 9.1x
#5067 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 29th percentile, 5-year average 101.1x
#4270 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 14.65 | – | 9.12 | 80% (pricier than usual) | #5067 of 5330 (1 = cheapest) |
| PE | 128.45 | 46.14 | -70.84 | 99% (pricier than usual) | #2874 of 2993 (1 = cheapest) |
| PS | 7.03 | 5.48 | 101.09 | 29% (cheaper than usual) | #4270 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ARQT.
Sign in to join the discussion.